CoChat

Epidemiology and Outcomes of Invasive Candidiasis Due to Non-albicans Species of Candida in 2,496 Patients: Data from the Prospective Antifungal Therapy (PATH) Registry 2004–2008

Open access

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.

Abstract

This analysis describes the epidemiology and outcomes of invasive candidiasis caused by non-albicans species of Candida in patients enrolled in the Prospective Antifungal Therapy Alliance (PATH Alliance) registry from 2004 to 2008. A total of 2,496 patients with non-albicans species of Candida isolates were identified. The identified species were C. glabrata (46.4%), C. parapsilosis (24.7%), C. tropicalis (13.9%), C. krusei (5.5%), C. lusitaniae (1.6%), C. dubliniensis (1.5%) and C. guilliermondii (0.4%); 111 infections involved two or more species of Candida (4.4%). Non-albicans species accounted for more than 50% of all cases of invasive candidiasis in 15 of the 24 sites (62.5%) that contributed more than one case to the survey. Among solid organ transplant recipients, patients with non-transplant surgery, and patients with solid tumors, the most prevalent non-albicans species was C. glabrata at 63.7%, 48.0%, and 53.8%, respectively. In 1,883 patients receiving antifungal therapy on day 3, fluconazole (30.5%) and echinocandins (47.5%) were the most frequently administered monotherapies. Among the 15 reported species, 90-day survival was highest for patients infected with either C. parapsilosis (70.7%) or C. lusitaniae (74.5%) and lowest for patients infected with an unknown species (46.7%) or two or more species (53.2%). In conclusion, this study expands the current knowledge of the epidemiology and outcomes of invasive candidiasis caused by non-albicans species of Candida in North America. The variability in species distribution in these centers underscores the importance of local epidemiology in guiding the selection of antifungal therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0101510

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 90-day survival stratified by non-albicans Candida species.
Figure 1 90-day survival stratified by non-albicans Candida species.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 69 references

Research works printed but not linked: 1

  1. D Horn, 2007, Contemporary patterns in the use of antifungal agents in the treatment of invasive fungal infections: perspectives from registries and databases, Curr Fungal Infect Rep, 1, 72

Cited by

See all 406

Metadata

Authors
Pfaller, M. A., Andes, D. R., Diekema, D. J., Horn, D. L., Reboli, A. C., Rotstein, C., Franks, B., & Azie, N. E.
Affiliations
  • University of Iowa (US)
  • University of Wisconsin–Madison (US)
  • Cooper Medical School of Rowan University (US)
  • University of Toronto (CA)
  • Astellas Pharma (United States) (US)
Corresponding author
Pfaller, Michael A.
Venue
PLoS ONE
Published
2014-07-03
Volume
9
Issue
7
Pages
e101510
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2053909542
Cited by
396
References
69
Citations by year
2026: 5 · 2025: 14 · 2024: 21 · 2023: 33 · 2022: 34 · 2021: 33 · 2020: 47 · 2019: 48 · 2018: 41 · 2017: 43 · 2016: 39 · 2015: 34 · 2014: 4
FWCI
28.12
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Pfizer
  • Massachusetts General Hospital
  • University of Nebraska Medical Center
  • University of Miami
  • University of Pennsylvania
  • Emory University
  • Bunning Food Allergy Institute, Ann and Robert H. Lurie Children's Hospital of Chicago
  • University of Minnesota
  • University of Washington
  • Johns Hopkins University
  • University of Pittsburgh
  • Hamilton Health Sciences
  • Thomas Jefferson University
  • University of Arkansas for Medical Sciences
  • City of Hope
  • Astellas Pharma
  • University of Texas MD Anderson Cancer Center
  • Medical Center, University of Pittsburgh
  • National Institute of Allergy and Infectious Diseases
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
  • Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
Keywords
invasive candidiasis, non-albicans Candida, Candida glabrata, Candida parapsilosis, Candida tropicalis, Candida krusei, Candida lusitaniae, Candida dubliniensis, Candida guilliermondii, Candida species distribution, antifungal therapy, fluconazole, echinocandins, 90-day survival, solid organ transplant recipients, solid tumors
MeSH terms
Adolescent, Adult, Aged, Aged, 80 and over, Antifungal Agents, Candida, Child, Child, Preschool, Drug Therapy, Combination, Female, Humans, Infant, Male, Middle Aged, Prospective Studies, Registries, Fluconazole, Prevalence, Survival Rate, Treatment Outcome, Echinocandins, Young Adult, Candidiasis, Invasive

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epidemiology and Outcomes of Invasive Candidiasis Due to Non-albicans Species of Candida in 2,496 Patients: Data from the Prospective Antifungal Therapy (PATH) Registry 2004–2008. https://app.cochat.ai/papers/10.1371/journal.pone.0101510
The paper
Pfaller, M. A., Andes, D. R., Diekema, D. J., Horn, D. L., Reboli, A. C., Rotstein, C., Franks, B., & Azie, N. E. (2014). Epidemiology and Outcomes of Invasive Candidiasis Due to Non-albicans Species of Candida in 2,496 Patients: Data from the Prospective Antifungal Therapy (PATH) Registry 2004–2008. PLoS ONE. https://doi.org/10.1371/journal.pone.0101510

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.